trial

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia

NCTId NCT01503359
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 70 (estimated)
Sponsored by Medical University of Lodz
Primary completion 2015-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
70 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-01
Primary completion
2015-02
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Sarcosine

Sponsors

Medical University of LodzLead Sponsor

Investigators

2
Dominik Strzelecki, MD, PhDPrincipal Investigator
Jolanta Rabe-Jabłońska, MD, PhDStudy Chair

Sites

1 total
Lodz, Poland

Linked catalysts

1
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glu — primary completion2015-02

Facts & assertions

4 sourced
Enrollment
70
Phase
PHASE2
Primary Completion Date
2015-02
Status
COMPLETED
relationships
The graph out of here
drug
Sarcosine
drug
lead_sponsor
Medical University of Lodz
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Dominik Strzelecki, MD, PhD
person
Jolanta Rabe-Jabłońska, MD, PhD
person